NASDAQ:PBM

Psyence Biomedical Q2 2027 Earnings Results & Report

Psyence Biomedical logo
$2.86 +0.35 (+13.94%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$2.87 +0.01 (+0.35%)
As of 08:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Psyence Biomedical reported Q2 2027 earnings on November 19, 2026. The company reported EPS of -$0.24.

Earnings Announcement Details

Quarter
Q2 2027
Time
Before Market Opens

Psyence Biomedical EPS Results

Actual EPS
-$0.24
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Psyence Biomedical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Psyence Biomedical Q2 2027 Earnings FAQ

Psyence Biomedical (NASDAQ:PBM) reported earnings of -$0.24 per share for Q2 2027. The report was announced on Thursday, November 19, 2026.

Psyence Biomedical Earnings Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
Psyence Biomedical Ltd. GAAP EPS of -$0.24
Psyence Biomedical (NASDAQ:PBM) Stock Falls 11.3% - Time to Sell?
See More Psyence Biomedical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Psyence Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Psyence Biomedical and other key companies, straight to your email.

About Psyence Biomedical

Psyence Biomedical (NASDAQ:PBM) is a clinical-stage biopharmaceutical company developing nature-derived psychedelic treatments for mental health and palliative care. Its research focuses on psilocybin, a psychedelic compound, for potential use in supervised therapeutic settings.

The company’s lead candidate, PEX010, is a naturally derived psilocybin product being studied for adjustment disorder in people receiving palliative care. Psyence Biomedical’s work centers on clinical development and evaluating the safety and potential therapeutic effects of this treatment.

Psyence Biomedical became a publicly traded company in 2024 through a business combination with Newcourt Acquisition Corp. It is part of the Psyence group, which has roots in psychedelic research and development.

View Psyence Biomedical Profile